Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study
No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program de...
Saved in:
| Published in | Cardiovascular diabetology Vol. 23; no. 1; pp. 57 - 12 |
|---|---|
| Main Authors | , , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central
08.02.2024
BMC |
| Subjects | |
| Online Access | Get full text |
| ISSN | 1475-2840 1475-2840 |
| DOI | 10.1186/s12933-024-02150-0 |
Cover
Loading…
| Abstract | No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups.
We identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE - MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3-4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF).
We identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex.
The cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD. |
|---|---|
| AbstractList | Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups. Methods We identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE – MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3–4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF). Results We identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex. Conclusions The cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD. No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups. We identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE - MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3-4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF). We identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex. The cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD. No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups.BACKGROUNDNo randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups.We identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE - MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3-4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF).METHODSWe identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE - MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3-4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF).We identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex.RESULTSWe identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex.The cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD.CONCLUSIONSThe cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD. BackgroundNo randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective effects in patients with a broad spectrum of cardiovascular risk. We reported the final-year results of the EMPRISE study, a monitoring program designed to evaluate the cardiorenal effectiveness of empagliflozin across broad patient subgroups.MethodsWe identified patients ≥ 18 years old with type 2 diabetes who initiated empagliflozin or GLP-1RA from 2014 to 2019 using US Medicare and commercial claims databases. After 1:1 propensity score matching using 143 baseline characteristics, we evaluated risks of outcomes including myocardial infarction (MI) or stroke, hospitalization for heart failure (HHF), major adverse cardiovascular events (MACE – MI, stroke, or cardiovascular mortality), a composite of HHF or cardiovascular mortality, and progression to end-stage kidney disease (ESKD) (in patients with chronic kidney disease stages 3–4). We estimated hazard ratios (HR) and rate differences (RD) per 1,000 person-years, overall and within subgroups of age, sex, baseline atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF).ResultsWe identified 141,541 matched pairs. Compared with GLP-1RA, empagliflozin was associated with similar risks of MI or stroke [HR: 0.99 (0.92, 1.07); RD: -0.23 (-1.25, 0.79)], and lower risks of HHF [HR: 0.50 (0.44, 0.56); RD: -2.28 (-2.98, -1.59)], MACE [HR: 0.90 (0.82, 0.99); RD: -2.54 (-4.76, -0.32)], cardiovascular mortality or HHF [HR: 0.77 (0.69, 0.86); RD: -4.11 (-5.95, -2.29)], and ESKD [0.75 (0.60, 0.94); RD: -6.77 (-11.97, -1.61)]. Absolute risk reductions were larger in older patients and in those with baseline ASCVD/HF. They did not differ by sex.ConclusionsThe cardiovascular benefits of empagliflozin vs. cardioprotective GLP-1RA agents were larger in older patients and in patients with history of ASCVD or HF, while they did not differ by sex. In patients with advanced CKD, empagliflozin was associated with risk reductions of progression to ESKD. |
| ArticleNumber | 57 |
| Author | Schmedt, Niklas Tesfaye, Helen Patorno, Elisabetta Glynn, Robert J. Htoo, Phyo T. Wexler, Deborah J. Everett, Brendan M. Schneeweiss, Sebastian Déruaz-Luyet, Anouk Paik, Julie M. Koeneman, Lisette |
| Author_xml | – sequence: 1 givenname: Phyo T. surname: Htoo fullname: Htoo, Phyo T. – sequence: 2 givenname: Helen surname: Tesfaye fullname: Tesfaye, Helen – sequence: 3 givenname: Sebastian surname: Schneeweiss fullname: Schneeweiss, Sebastian – sequence: 4 givenname: Deborah J. surname: Wexler fullname: Wexler, Deborah J. – sequence: 5 givenname: Brendan M. surname: Everett fullname: Everett, Brendan M. – sequence: 6 givenname: Robert J. surname: Glynn fullname: Glynn, Robert J. – sequence: 7 givenname: Niklas surname: Schmedt fullname: Schmedt, Niklas – sequence: 8 givenname: Lisette surname: Koeneman fullname: Koeneman, Lisette – sequence: 9 givenname: Anouk surname: Déruaz-Luyet fullname: Déruaz-Luyet, Anouk – sequence: 10 givenname: Julie M. surname: Paik fullname: Paik, Julie M. – sequence: 11 givenname: Elisabetta surname: Patorno fullname: Patorno, Elisabetta |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38331813$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kkuLFDEUhQsZcR76B1xIwM1sasyrUok7aVptGFF8rMOt1E2btrrSJqmBdusft6Z7RmQWLkIuud85hHvPeXUyxhGr6jmjV4xp9SozboSoKZfzYQ2t6aPqjMm2qbmW9OSf-rQ6z3lDKWu1Yk-qU6GFYJqJs-r3AlIfYsIRBoLeoyvhBkfMmURPcLuD9RD8EH-FkdzkK7IeJgfrONZD-IFkh7sSeqwZSejmOiZy2wy55NfEh9mz3iOkuZunoWTiU9yS8h3J8sOnz6svS5LL1O-fVo89DBmf3d0X1be3y6-L9_X1x3erxZvr2jVUl9pJRYVhXHRKo24NGA1SGdcYxb2RwFouXeeh09KrtgHdg-cSjULPXANeXFSro28fYWN3KWwh7W2EYA8PMa0tpBLcgBYkNT1g2-leyc77zqnWdwK0Q5RUdbPX5dFrl-LPCXOx25AdDgOMGKdsueHSGNUaPqMvH6CbOKV5NgeqUUIprWbqxR01dVvs_37vflUzoI-ASzHnhN66UKCEOJYEYbCM2ttU2GMq7JwKe0iFpbOUP5Deu_9H9AcVr7rR |
| CitedBy_id | crossref_primary_10_1111_dom_15696 crossref_primary_10_1038_s41598_025_93483_7 crossref_primary_10_2337_dc24_0270 crossref_primary_10_3390_biomedicines12051102 crossref_primary_10_1111_dom_15710 crossref_primary_10_1016_j_jacc_2024_06_028 crossref_primary_10_7759_cureus_73705 crossref_primary_10_1111_dom_15682 crossref_primary_10_2478_prilozi_2024_0027 crossref_primary_10_3389_fnut_2024_1510403 crossref_primary_10_1186_s12933_024_02190_6 |
| Cites_doi | 10.1136/bmjdrc-2020-001451 10.1093/aje/kwy078 10.1038/s41467-022-32310-3 10.1001/jamacardio.2020.4511 10.1002/pds.1200 10.1111/dom.13184 10.1093/aje/kwg231 10.1056/NEJMoa2204233 10.1161/JAHA.121.022376 10.18553/jmcp.2020.26.5.610 10.1016/j.diabres.2021.108800 10.2337/cd17-0119 10.1056/NEJMoa1504720 10.1093/biomet/70.1.41 10.1093/ehjcvp/pvab053 10.1097/01.mlr.0000160417.39497.a9 10.1016/S0140-6736(18)32590-X 10.1016/S2213-8587(21)00203-5 10.1002/sim.3697 10.1093/gerona/glz224 10.1016/j.ahj.2004.02.013 10.1001/jamanetworkopen.2022.37606 10.1161/JAHA.120.019356 10.1016/j.ijcard.2022.01.042 10.1002/sim.6058 10.1016/j.ijcard.2022.06.027 10.1186/s12933-021-01258-x 10.1186/s12933-022-01572-y 10.1161/STROKEAHA.114.006316 10.2337/cd16-0067 10.2337/dc20-1464 10.1111/dom.14741 10.1016/j.diabres.2021.109071 10.1002/pds.5398 10.1016/j.jclinepi.2010.10.004 10.1097/EDE.0b013e3181a663cc 10.7326/M21-0893 10.1038/clpt.2011.235 10.1161/JAHA.116.004966 10.1111/dom.14598 10.1002/edm2.103 |
| ContentType | Journal Article |
| Copyright | 2024. The Author(s). 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| Copyright_xml | – notice: 2024. The Author(s). – notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7T5 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 DOA |
| DOI | 10.1186/s12933-024-02150-0 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Immunology Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea ProQuest Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni) Medical Database ProQuest Central Premium ProQuest One Academic (New) ProQuest Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition Immunology Abstracts ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1475-2840 |
| EndPage | 12 |
| ExternalDocumentID | oai_doaj_org_article_a409dae7b8d64bffbc67fb3a8cee406b 38331813 10_1186_s12933_024_02150_0 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GeographicLocations | United States United States--US |
| GeographicLocations_xml | – name: United States – name: United States--US |
| GrantInformation_xml | – fundername: Boehringer Ingelheim grantid: 116283 |
| GroupedDBID | --- 0R~ 29B 2WC 53G 5GY 5VS 6J9 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO RBZ RNS ROL RPM RSV SMD SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM PMFND 3V. 7T5 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 PUEGO |
| ID | FETCH-LOGICAL-c508t-c46039123b68e879a98a469c5962f94a1724cbfab84f675a8daf24e96ef1c5af3 |
| IEDL.DBID | M48 |
| ISSN | 1475-2840 |
| IngestDate | Wed Aug 27 01:29:37 EDT 2025 Thu Jul 10 18:35:35 EDT 2025 Fri Jul 25 22:47:56 EDT 2025 Tue Jun 10 08:58:26 EDT 2025 Tue Jul 01 04:20:01 EDT 2025 Thu Apr 24 23:07:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Type 2 diabetes Empagliflozin Effectiveness Cardiovascular disease GLP-1RA Chronic kidney disease SGLT2i |
| Language | English |
| License | 2024. The Author(s). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c508t-c46039123b68e879a98a469c5962f94a1724cbfab84f675a8daf24e96ef1c5af3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b |
| PMID | 38331813 |
| PQID | 2925636686 |
| PQPubID | 42570 |
| PageCount | 12 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_a409dae7b8d64bffbc67fb3a8cee406b proquest_miscellaneous_2924996792 proquest_journals_2925636686 pubmed_primary_38331813 crossref_citationtrail_10_1186_s12933_024_02150_0 crossref_primary_10_1186_s12933_024_02150_0 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2024-02-08 |
| PublicationDateYYYYMMDD | 2024-02-08 |
| PublicationDate_xml | – month: 02 year: 2024 text: 2024-02-08 day: 08 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Cardiovascular diabetology |
| PublicationTitleAlternate | Cardiovasc Diabetol |
| PublicationYear | 2024 |
| Publisher | BioMed Central BMC |
| Publisher_xml | – name: BioMed Central – name: BMC |
| References | E Patorno (2150_CR46) 2018; 20 IB Poonawalla (2150_CR17) 2021; 175 A American Diabetes (2150_CR37) 2017; 35 E Patorno (2150_CR5) 2021; 44 ED Pineda (2150_CR15) 2020; 26 ME Hill (2150_CR27) 2001; 64 DK McGuire (2150_CR4) 2021; 6 2150_CR9 CH Kim (2150_CR12) 2022; 364 E Birman-Deych (2150_CR26) 2005; 43 S Schneeweiss (2150_CR36) 2011; 90 S Schneeweiss (2150_CR41) 2009; 20 PC Austin (2150_CR34) 2009; 28 CH Nørgaard (2150_CR8) 2021; 8 2150_CR7 The EMPA-KIDNEY Collaborative Group (2150_CR44) 2022; 388 Y Kiyota (2150_CR25) 2004; 148 2150_CR45 2150_CR20 2150_CR21 2150_CR43 JJ Gagne (2150_CR30) 2011; 64 N Sattar (2150_CR2) 2021; 9 JE Ripollone (2150_CR33) 2018; 187 JM Franklin (2150_CR35) 2014; 33 2150_CR28 E Longato (2150_CR11) 2020; 8 EL Fu (2150_CR18) 2022; 352 PT Htoo (2150_CR19) 2022; 5 S Schneeweiss (2150_CR42) 2006; 15 WA Ray (2150_CR22) 2003; 158 JM Paik (2150_CR23) 2022; 31 YH Dong (2150_CR10) 2022; 24 NA ElSayed (2150_CR40) 2022; 46 A American Diabetes (2150_CR38) 2018; 36 PR Rosenbaum (2150_CR32) 1983; 70 TA Zelniker (2150_CR3) 2019; 393 2150_CR13 EHM Tang (2150_CR14) 2021; 180 E Patorno (2150_CR6) 2021; 174 SA Jones (2150_CR24) 2014; 45 OT Olubowale (2150_CR29) 2017; 6 B Zinman (2150_CR1) 2015; 373 2150_CR16 2150_CR39 DH Kim (2150_CR31) 2020; 75 38500096 - Cardiovasc Diabetol. 2024 Mar 18;23(1):103. doi: 10.1186/s12933-024-02190-6 |
| References_xml | – volume: 8 start-page: e001451 issue: 1 year: 2020 ident: 2150_CR11 publication-title: BMJ Open Diabetes Res Care doi: 10.1136/bmjdrc-2020-001451 – volume: 187 start-page: 1951 issue: 9 year: 2018 ident: 2150_CR33 publication-title: Am J Epidemiol doi: 10.1093/aje/kwy078 – ident: 2150_CR43 doi: 10.1038/s41467-022-32310-3 – volume: 6 start-page: 148 issue: 2 year: 2021 ident: 2150_CR4 publication-title: JAMA Cardiol doi: 10.1001/jamacardio.2020.4511 – volume: 15 start-page: 291 issue: 5 year: 2006 ident: 2150_CR42 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.1200 – volume: 20 start-page: 974 issue: 4 year: 2018 ident: 2150_CR46 publication-title: Diabetes Obes Metab doi: 10.1111/dom.13184 – volume: 46 start-page: 140 issue: Supplement1 year: 2022 ident: 2150_CR40 publication-title: Diabetes Care – volume: 158 start-page: 915 issue: 9 year: 2003 ident: 2150_CR22 publication-title: Am J Epidemiol doi: 10.1093/aje/kwg231 – volume: 388 start-page: 117 issue: 2 year: 2022 ident: 2150_CR44 publication-title: N Engl J Med doi: 10.1056/NEJMoa2204233 – ident: 2150_CR7 doi: 10.1161/JAHA.121.022376 – volume: 26 start-page: 610 issue: 5 year: 2020 ident: 2150_CR15 publication-title: J Managed Care Specialty Pharm doi: 10.18553/jmcp.2020.26.5.610 – volume: 175 start-page: 108800 year: 2021 ident: 2150_CR17 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2021.108800 – volume: 36 start-page: 14 issue: 1 year: 2018 ident: 2150_CR38 publication-title: Clin Diabetes doi: 10.2337/cd17-0119 – volume: 373 start-page: 2117 issue: 22 year: 2015 ident: 2150_CR1 publication-title: N Engl J Med doi: 10.1056/NEJMoa1504720 – volume: 70 start-page: 41 issue: 1 year: 1983 ident: 2150_CR32 publication-title: Biometrika doi: 10.1093/biomet/70.1.41 – volume: 8 start-page: 549 issue: 6 year: 2021 ident: 2150_CR8 publication-title: Eur Heart J - Cardiovasc Pharmacotherapy doi: 10.1093/ehjcvp/pvab053 – volume: 43 start-page: 480 issue: 5 year: 2005 ident: 2150_CR26 publication-title: Med Care doi: 10.1097/01.mlr.0000160417.39497.a9 – ident: 2150_CR45 – volume: 393 start-page: 31 issue: 10166 year: 2019 ident: 2150_CR3 publication-title: Lancet doi: 10.1016/S0140-6736(18)32590-X – volume: 9 start-page: 653 issue: 10 year: 2021 ident: 2150_CR2 publication-title: Lancet Diabetes Endocrinol doi: 10.1016/S2213-8587(21)00203-5 – volume: 28 start-page: 3083 issue: 25 year: 2009 ident: 2150_CR34 publication-title: Stat Med doi: 10.1002/sim.3697 – volume: 75 start-page: 1120 issue: 6 year: 2020 ident: 2150_CR31 publication-title: J Gerontol Biol Sci Med Sci doi: 10.1093/gerona/glz224 – ident: 2150_CR28 – volume: 148 start-page: 99 issue: 1 year: 2004 ident: 2150_CR25 publication-title: Am Heart J doi: 10.1016/j.ahj.2004.02.013 – volume: 5 start-page: e2237606 issue: 10 year: 2022 ident: 2150_CR19 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2022.37606 – ident: 2150_CR20 doi: 10.1161/JAHA.120.019356 – volume: 352 start-page: 172 year: 2022 ident: 2150_CR18 publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2022.01.042 – volume: 33 start-page: 1685 issue: 10 year: 2014 ident: 2150_CR35 publication-title: Stat Med doi: 10.1002/sim.6058 – volume: 364 start-page: 104 year: 2022 ident: 2150_CR12 publication-title: Int J Cardiol doi: 10.1016/j.ijcard.2022.06.027 – ident: 2150_CR16 doi: 10.1186/s12933-021-01258-x – ident: 2150_CR13 doi: 10.1186/s12933-022-01572-y – volume: 45 start-page: 3219 issue: 11 year: 2014 ident: 2150_CR24 publication-title: Stroke doi: 10.1161/STROKEAHA.114.006316 – volume: 35 start-page: 5 issue: 1 year: 2017 ident: 2150_CR37 publication-title: Clin Diabetes doi: 10.2337/cd16-0067 – volume: 44 start-page: 826 issue: 3 year: 2021 ident: 2150_CR5 publication-title: Diabetes Care doi: 10.2337/dc20-1464 – volume: 24 start-page: 1623 issue: 8 year: 2022 ident: 2150_CR10 publication-title: Diabetes Obes Metab doi: 10.1111/dom.14741 – volume: 180 start-page: 109071 year: 2021 ident: 2150_CR14 publication-title: Diabetes Res Clin Pract doi: 10.1016/j.diabres.2021.109071 – ident: 2150_CR39 – volume: 31 start-page: 467 issue: 4 year: 2022 ident: 2150_CR23 publication-title: Pharmacoepidemiol Drug Saf doi: 10.1002/pds.5398 – volume: 64 start-page: 749 issue: 7 year: 2011 ident: 2150_CR30 publication-title: J Clin Epidemiol doi: 10.1016/j.jclinepi.2010.10.004 – volume: 20 start-page: 512 issue: 4 year: 2009 ident: 2150_CR41 publication-title: Epidemiology doi: 10.1097/EDE.0b013e3181a663cc – volume: 174 start-page: 1528 year: 2021 ident: 2150_CR6 publication-title: Ann Intern Med doi: 10.7326/M21-0893 – volume: 64 start-page: 45 issue: 1 year: 2001 ident: 2150_CR27 publication-title: Soc Secur Bull – volume: 90 start-page: 777 issue: 6 year: 2011 ident: 2150_CR36 publication-title: Clin Pharmacol Ther doi: 10.1038/clpt.2011.235 – volume: 6 start-page: e004966 issue: 5 year: 2017 ident: 2150_CR29 publication-title: J Am Heart Association doi: 10.1161/JAHA.116.004966 – ident: 2150_CR9 doi: 10.1111/dom.14598 – ident: 2150_CR21 doi: 10.1002/edm2.103 – reference: 38500096 - Cardiovasc Diabetol. 2024 Mar 18;23(1):103. doi: 10.1186/s12933-024-02190-6 |
| SSID | ssj0017861 |
| Score | 2.4325073 |
| Snippet | No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated cardioprotective... BackgroundNo randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated... Abstract Background No randomized clinical trials have directly compared the cardiorenal effectiveness of empagliflozin and GLP-1RA agents with demonstrated... |
| SourceID | doaj proquest pubmed crossref |
| SourceType | Open Website Aggregation Database Index Database Enrichment Source |
| StartPage | 57 |
| SubjectTerms | Adolescent Aged Angina pectoris Antidiabetics Arteriosclerosis Atherosclerosis - drug therapy Benzhydryl Compounds Cardiovascular disease Cardiovascular diseases Cardiovascular Diseases - diagnosis Cardiovascular Diseases - epidemiology Cardiovascular Diseases - prevention & control Cerebral infarction Chronic illnesses Chronic kidney disease Clinical outcomes Clinical trials Congestive heart failure Diabetes Diabetes mellitus (non-insulin dependent) Diabetes Mellitus, Type 2 - diagnosis Diabetes Mellitus, Type 2 - drug therapy Diabetes Mellitus, Type 2 - epidemiology Disease Empagliflozin End-stage renal disease GLP-1 receptor agonists GLP-1RA Glucagon Glucagon-like peptide 1 Glucagon-Like Peptide-1 Receptor Glucagon-Like Peptide-1 Receptor Agonists Glucosides Health risks Heart diseases Heart failure Heart Failure - diagnosis Heart Failure - drug therapy Heart Failure - epidemiology Humans Hypoglycemic Agents - adverse effects Insurance coverage Ischemia Kidney diseases Laboratories Medicare Mortality Myocardial infarction Patients Peptides Performance evaluation Pharmacy Population Prescriptions Sex SGLT2i Sodium-Glucose Transporter 2 Inhibitors - adverse effects Stroke Stroke - diagnosis Stroke - epidemiology Stroke - prevention & control Type 2 diabetes United States |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1LbxQxDI5QD4gL4s1Ci4LEDYXOI-tJuLXVVgVpEQIq9RYls3G1YjRT7exWKtf-cezM7AoOwIXbaOJoMrFj-5MdW4g3BqyJHPpHnAYuqq2VAU1QxUAOfGmgTKGY-Sc4O9cfL6YXv7T64pywoTzwsHGHngDIwscqmAXogBhqqDCU3pB2J2MUWPuSzduCqTF-UNGntldkDBz2bNU4XqkV27hMZb-ZoVSt_88uZjI1pw_E_dFHlEfD2h6KO7F9JO7Oxyj4Y3F7kpJIV5GphoSMUWfJDmWkA37ZLLHpfixbed2_k5yW7i-7VjXL71FecR7LIqpckrKj524leZDY3b-XyE2y1A2JP432m2bdS76AIslNlLP55y8fvs5kqkj7RJyfzr6dnKmxmYKqyQdbq1oDF4MvygAmmsp6azxB45q776DVnhwZXQf0wWgkEOHNwmOho4WIeT31WD4Ve23XxudCTm2G5JhHrHTUNhiaHcrKED8gx1DBROTbvXX1WGmcG140LiEOA27ghyN-uMQPl03E292cq6HOxl-pj5llO0qukZ1ekOS4UXLcvyRnIva3DHfjwe1dYckHLAEM_cXr3TAdOY6j-DZ2m0RDOBEqW0zEs0FQdishwE9aMi9f_I8VvhT3ikFmVWb2xd56tYkH5AOtw6sk7j8BeE0ERQ priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEA96gvgifls9JYJvEq8f2Xz4InrscQoroh7sW0jaZFmutOt2V9BX_3Fn0mzFB--tNJO2dDIzv8lMZgh5qYRWHkP_IcwcFtXmTAkOrooShcBDA1UMxSw-ifML_nE5W6YNtyGlVR50YlTUTV_jHvlJqcE4V0Io8XbznWHXKIyuphYa18kNLF2GKV1yOTlchYQXHg7KKHEyoG3DqCVnaOlylv9jjGLN_v8DzWhwzu6Q2wkp0ncja--Sa767R24uUiz8Pvl9GlNJtx6pxrSMpLloH6gHMV-169D2v9Yd_TG8ppicbld9x9r1pacbzGZpPCsoqDy47rcUB4HpwxsasFUW-wlCAKPDvt0NFI-hUACLdL74_OXD1zmNdWkfkIuz-bfTc5ZaKrAakNiO1VxgSfiyckJ5JbXVyoKDXGMPnqC5BTjDaxesUzyAK2FVY0PJvRY-FPXMhuohOer6zj8mdKbzAPDcB8k9107BbFdJ5T0XRXBSZKQ4_FtTp3rj2PaiNdHvUMKM_DDADxP5YfKMvJrmbMZqG1dSv0eWTZRYKTve6LcrkwTPWHBgG-ulU43gLgRXCxlcZRWgAwAzLiPHB4abJL6D-bvYMvJiGgbBw2iK7Xy_jzTgLQqpy4w8GhfK9CXg9oOuLKonVz_8KblVjquR5eqYHO22e_8MMM7OPY8L-Q9xQvlz priority: 102 providerName: ProQuest |
| Title | Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/38331813 https://www.proquest.com/docview/2925636686 https://www.proquest.com/docview/2924996792 https://doaj.org/article/a409dae7b8d64bffbc67fb3a8cee406b |
| Volume | 23 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swEBddC6UvY9_N1gUN9jbUxbaij8EYa0npBimlWyBvQnKkEGbszk7Gutf947uT7YxBuzdjSSDr7nS_n0-6I-S1Elp5DP2HMHaYVJszJThQFSUSgZcGshiKmV6I8xn_PB_Pd0hf7qhbwOZWaof1pGZ1cfzz-80HMPj30eCVeNugz8JoJGfowUYMKPweeCaJhjrlf6MKEibQX5y5ddwB2QfGBmqeZP_4qZjO_24MGn3R2QNyvwOR9GMr9Ydkx5ePyP60C5M_Jr9P4ynT2mOv9sRGt6nRKlAPO8CyWIWi-rUq6Y_mmOK5dbusSlasvnl6jQddFp4lFHZDeK5qio2gD807GrCKFrsB-4DWZlOsG4o3VCjgSDqZXl59-jKhMWXtEzI7m3w9PWddtQWWA0hbs5wLzBafZk4or6S2WlngzjmW5wmaW0A6PHfBOsUDsAyrFjak3GvhQ5KPbciekt2yKv0hoWM9CoDcfZDcc-0UjHaZVN5zkQQnxYAk_dqavEtFjhUxChMpiRKmFY0B0ZgoGjMakDfbMddtIo7_9j5BkW17YhLt-KKql6azSWOB2y6sl04tBHchuFzI4DKrADgAznEDctQL3PSKaVINIDETQsFXvNo2g01ioMWWvtrEPkAkhdTpgDxrFWU7k16_nt_Z8oIcpK1OspE6IrvreuNfAvJZuyG5J-dySPZOJheXV8P4_2AYVfwP3Yn_vA |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CqtBFwQb1IKGAlOyDQPr-MgIUTLVru0u6pKK_Vm7MRerRoly2YXVK78D9_ITF6IA731FsVjK_aM55F5EfJKikRadP07NzBYVJszKTiYKlIEApMGotoVM5mK0Rn_fD443yC_u1wYDKvseGLNqLMyxX_ku2ECwjkSQooPi28Mu0ahd7VrodGQxaG9_AEmW_V-_Anw-zoMD4an-yPWdhVgKSgjK5ZygVXRw8gIaWWc6ERqsBFTbEPjEq5BovPUOG0kd6BNa5lpF3KbCOuCdKBdBOveIFsc9gGMYGtvOD0-6f0WMWyxS82RYrdCaYp-Us5QtvrM_0f81V0C_q_a1iLu4C650-qm9GNDTPfIhi3uk5uT1vv-gPzar4NXlxahmkCQllfS0lELjGWWz11e_pwX9Hv1lmI4vJ6VBcvnF5YuMH4msyygwGThuVxSHAQyq95Rh8252CWcL4xW63xVUUx8oaCe0uHk-GT8ZUjrSrgPydm1HPcjslmUhX1C6CDxHRgE1sXc8sRImG2iWFrLReBMLDwSdGer0rbCOTbayFVt6UihGnwowIeq8aF8j7zp5yya-h5XQu8hynpIrM1dvyiXM9VedaXBZM60jY3MBDfOmVTEzkRagj4C6pPxyE6HcNUyjEr9JW-PvOyH4aqj_0YXtlzXMGCfijgJPfK4IZT-SyIZAXcOou2rF39Bbo1OJ0fqaDw9fEpuhw1lMl_ukM3Vcm2fgYa1Ms9bsqbk63XfpD8VWzfP |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cardiorenal+effectiveness+of+empagliflozin+vs.+glucagon-like+peptide-1+receptor+agonists%3A+final-year+results+from+the+EMPRISE+study&rft.jtitle=Cardiovascular+diabetology&rft.au=Htoo%2C+Phyo+T&rft.au=Tesfaye%2C+Helen&rft.au=Schneeweiss%2C+Sebastian&rft.au=Wexler%2C+Deborah+J&rft.date=2024-02-08&rft.eissn=1475-2840&rft.volume=23&rft.issue=1&rft.spage=57&rft_id=info:doi/10.1186%2Fs12933-024-02150-0&rft_id=info%3Apmid%2F38331813&rft.externalDocID=38331813 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1475-2840&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1475-2840&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1475-2840&client=summon |